ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Nicox SA

Nicox SA (ALCOX)

0,30
-0,001
( -0,33% )
Aktualisiert: 15:25:19

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
0,30
Gebot
0,2985
Fragen
0,3035
Volumen
40.796
0,297 Tagesbereich 0,305
0,14 52-Wochen-Bereich 0,4915
Marktkapitalisierung
Handelsende
0,301
Handelsbeginn
0,304
Letzte Trade
5319
@
0.3
Letzter Handelszeitpunkt
15:25:19
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
144.883
Ausgegebene Aktien
50.299.694
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-13,66
Gewinn pro Aktie (EPS)
-0,42
Erlöse
7,14M
Nettogewinn
-20,88M

Über Nicox SA

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
Hauptsitz
Antibes, Alpes-maritimes, Fra
Gegründet
-
Nicox SA is listed in the Pharmaceutical Preparations sector of the Euronext with ticker ALCOX. The last closing price for Nicox was 0,30 €. Over the last year, Nicox shares have traded in a share price range of 0,14 € to 0,4915 €.

Nicox currently has 50.299.694 shares in issue. The market capitalisation of Nicox is 15,14 € million. Nicox has a price to earnings ratio (PE ratio) of -13.66.

ALCOX Neueste Nachrichten

Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights

Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights Press Release Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights Last patient recruited in the...

Nicox : Point d’activité et résumé financier du quatrième trimestre 2024

Nicox : Point d’activité et résumé financier du quatrième trimestre 2024 Communiqué de presseNicox : Point d’activité et résumé financier du quatrième trimestre 2024  Recrutement du dernier...

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream Press Release Nicox Announces First Commercial Sale of ZERVIATE in China...

Nicox annonce la première vente commerciale de ZERVIATE en Chine par son partenaire Ocumension, création d’une nouvelle source de revenus récurrents

Nicox annonce la première vente commerciale de ZERVIATE en Chine par son partenaire Ocumension, création d’une nouvelle source de revenus récurrents Communiqué de presseNicox annonce la première...

Nicox : Recrutement de patients achevé plus tôt que prévu en Chine dans l’étude clinique de phase 3 Denali sur NCX 470

Nicox : Recrutement de patients achevé plus tôt que prévu en Chine dans l’étude clinique de phase 3 Denali sur NCX 470 Communiqué de presseNicox : Recrutement de patients achevé plus tôt que prévu...

Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected

Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected Press ReleaseNicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected Confirms...

Nicox annonce la publication de la partie adaptive de l’étude clinique de phase 3 Mont Blanc sur NCX 470

Nicox annonce la publication de la partie adaptive de l’étude clinique de phase 3 Mont Blanc sur NCX 470 Communiqué de presseNicox annonce la publication de la partie adaptive de l’étude clinique...

Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial

Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial Press Release Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc...

Nicox : Point financier sur le troisième trimestre 2024 et résultats financiers du premier semestre 2024

Nicox : Point financier sur le troisième trimestre 2024 et résultats financiers du premier semestre 2024 Communiqué de presseNicox : Point financier sur le troisième trimestre 2024 et résultats...

Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results

Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Press Release Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results  Topline results from...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.0095-3.069466882070.30950.31650.293793640.30302842DE
40.01053.626943005180.28950.3350.2811416830.30830459DE
120.0415.38461538460.260.3350.20051448830.2786759DE
260.122869.30022573360.17720.3350.142550940.25662255DE
52-0.109-26.65036674820.4090.49150.141739420.2655362DE
156-0.282-48.45360824740.5820.650.141375480.31860216DE
260-0.282-48.45360824740.5820.650.141375480.31860216DE

ALCOX - Frequently Asked Questions (FAQ)

What is the current Nicox share price?
The current share price of Nicox is 0,30 €
How many Nicox shares are in issue?
Nicox has 50.299.694 shares in issue
What is the market cap of Nicox?
The market capitalisation of Nicox is EUR 15,14M
What is the 1 year trading range for Nicox share price?
Nicox has traded in the range of 0,14 € to 0,4915 € during the past year
What is the PE ratio of Nicox?
The price to earnings ratio of Nicox is -13,66
What is the cash to sales ratio of Nicox?
The cash to sales ratio of Nicox is 39,93
What is the reporting currency for Nicox?
Nicox reports financial results in EUR
What is the latest annual turnover for Nicox?
The latest annual turnover of Nicox is EUR 7,14M
What is the latest annual profit for Nicox?
The latest annual profit of Nicox is EUR -20,88M
What is the registered address of Nicox?
The registered address for Nicox is SUNDESK SOPHIA ANTIPOLIS ,EMERALD SQUARE, B��TIMENT C, RUE EVARISTE GALOIS, BIOT, ANTIBES, ALPES-MARITIMES, 06410
What is the Nicox website address?
The website address for Nicox is www.nicox.com
Which industry sector does Nicox operate in?
Nicox operates in the PHARMACEUTICAL PREPARATIONS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
DMSBSDiagnostic Medical Systems
0,007 €
(75,00%)
36,27k
GTRDSGroupe Tera DS
0,124 €
(48,50%)
32,35k
POXELPoxel
0,3295 €
(35,04%)
4,62M
ALDOLDolfines
4,089 €
(20,09%)
70,89k
EEMElectricite et Eaux de Madagascar
4,30 €
(16,22%)
50
HYPDSHipay Group DS
0,011 €
(-45,00%)
14,43k
DRVDSDrone Volt DS
0,001 €
(-44,44%)
615,05k
NICBSNicox SA
0,0178 €
(-22,61%)
11
ALGENGenoway S A Inh Eo 15
3,02 €
(-20,73%)
100,9k
ALGBEGlobal Bioenergies
0,94 €
(-18,97%)
79,94k
ATOAtos SE
0,0022 €
(10,00%)
2,96B
BCPBanco Comercial Portugues SA
0,5112 €
(0,79%)
45,3M
ALVERVergnet
0,0015 €
(0,00%)
18,79M
ALCYBCybergun
0,0001 €
(0,00%)
13,6M
ALADOAdomos
0,0002 €
(0,00%)
10,2M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock